ABSTRACT
Poly(alkyl cyanoacrylates) with a higher alkyl chain length is relatively less toxic than those with a lower alkyl chain length. Several interesting studies were reported on the usefulness of poly(alkyl cyanoacrylates) for delivering anti-cancer drugs to different types of cancers, including breast cancer and gastric cancer. Interesting results were observed in the case of delivery of doxorubicin-loaded poly(alkyl cyanoacrylate) nanoparticles for the treatment of liver tumors. Though the initial results on the delivery of doxorubicin-loaded poly-butylcyanoacrylate nanoparticles to lymphoma are encouraging, more experimental evidence is needed to evaluate their efficacy on tumors. The poly (ethylene glycol) modification of alkylcyanoacrylates has improved the delivery of their nanoparticles to the brain. Reports on the importance of nanoparticles in reversion of multi-drug resistance mediated by P-glycoprotein in multi-drug resistant (MDR) tumors reveal the potential of using poly(isobutyl cyanoacrylate) nanoparticles in MDR tumors. For solid tumors, extravasation could be followed by a rapid degradation of the polymer, leading to a rapid drug release.
